VUZE Medical received additional patents for its VUZE™ System in the U.S., Europe and China. Using proprietary image processing, the VUZE System is a software-only application that overlays a graphical representation of tools seen in intra-operative 2D images onto axial and sagittal views generated from the patient’s standard pre-operative 3D scan. FDA 510(k) clearance was granted in January 2022.
Chinese Patent No. 109195527B and European Patent No. 3429475 follow previously issued U.S. Patent No. 10716631 in describing the core workflow of the VUZE System. Additionally, U.S. Patent No. 11224483 describes a unique form of 2D/3D image co-registration via machine learning in which the learning phase is performed solely upon the 3D scan of the same patient of whom 2D images are later acquired.
Currently in clinical validation, the VUZE System is designed for use during common spinal stabilization surgeries that are performed in outpatient or ambulatory settings and are currently aided solely by x-ray. The system uses no sensors, cameras or reference arrays whatsoever, nor does it require any calibrations or lines of sight. It can be used with standard surgical tools and implants, with no tool add-ons or modifications.
“These new patents further establish our intellectual property as one of the unique strengths of the VUZE solution,” said David Tolkowsky, VUZE Medical’s CEO. “We believe that our continued commitment to investing in IP will translate in the near future into further patents granted worldwide.”
VUZE Medical received additional patents for its VUZE™ System in the U.S., Europe and China. Using proprietary image processing, the VUZE System is a software-only application that overlays a graphical representation of tools seen in intra-operative 2D images onto axial and sagittal views generated from the patient’s standard pre-operative 3D...
VUZE Medical received additional patents for its VUZE™ System in the U.S., Europe and China. Using proprietary image processing, the VUZE System is a software-only application that overlays a graphical representation of tools seen in intra-operative 2D images onto axial and sagittal views generated from the patient’s standard pre-operative 3D scan. FDA 510(k) clearance was granted in January 2022.
Chinese Patent No. 109195527B and European Patent No. 3429475 follow previously issued U.S. Patent No. 10716631 in describing the core workflow of the VUZE System. Additionally, U.S. Patent No. 11224483 describes a unique form of 2D/3D image co-registration via machine learning in which the learning phase is performed solely upon the 3D scan of the same patient of whom 2D images are later acquired.
Currently in clinical validation, the VUZE System is designed for use during common spinal stabilization surgeries that are performed in outpatient or ambulatory settings and are currently aided solely by x-ray. The system uses no sensors, cameras or reference arrays whatsoever, nor does it require any calibrations or lines of sight. It can be used with standard surgical tools and implants, with no tool add-ons or modifications.
“These new patents further establish our intellectual property as one of the unique strengths of the VUZE solution,” said David Tolkowsky, VUZE Medical’s CEO. “We believe that our continued commitment to investing in IP will translate in the near future into further patents granted worldwide.”
Copy to clipboard 
